Lei Lei Wu is a news reporter for Endpoints News, specializing in reporting on drugs and biotechs. With a focus on the pharmaceutical industry, Lei Lei covers topics such as clinical trial results, FDA approvals, and biotech company developments.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Lei Lei Wu's coverage is heavily focused on the healthcare and pharmaceutical industry, particularly on biotechnology, pharmaceutical companies, gene therapy, clinical trials, and drug development. The majority of her articles are based on press releases and cite data.
Given this focus, she would likely be interested in receiving pitches related to new developments in biotechnology or pharmaceuticals backed by solid data or press releases. Pitches offering insights from experts within these fields regarding groundbreaking studies or significant advancements in drug development may resonate with her. Additionally, providing access to exclusive data or early access to important press releases could enhance the effectiveness of outreach efforts.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Lei Lei Wu
AvenCell Therapeutics on Tuesday said it collected $112 million to continue clinical studies of two experimental acute myeloid leukemia CAR-T cell therapies. The Series B raise comes despite cold investor ...
Merck is acquiring a startup spun out of Yale called Modifi Bio, which has developed a suite of molecules against chemotherapy-resistant glioblastoma, a devastating and often deadly disease. Merck will ...
By: Lei Lei Wu
In an interview Friday, Revolution Medicines CEO Mark Goldsmith, who says he prefers to understate rather than exaggerate, floated a lofty goal: cure pancreatic cancer — or get close. “That's our ...
The story of cancer has long started with a single mutated cell that divides and eventually grows into a tumor causing disease and death. …
Lexeo Therapeutics shared biomarker data from 15 patients in a Phase 1/2 study of its gene therapy for Alzheimer's disease. …
By: Alex Hoffman, Kathy Wong
Alan Bash is joining Legend Biotech as its president of Carvykti , an unconventional, newly-created role to oversee the commercial future of …
By: Gene Tx
US regulators gave the green light to Autolus Therapeutics' cell therapy for adult B-cell precursor acute lymphoblastic leukemia, or B-ALL, that has returned or is not responding to prior treatment.
TRexBio secured $84 million Series B funding, led by Delos Capital with Eli Lilly and Johnson & Johnson participating, to advance clinical studies for their TNFR2 agonist targeting atopic dermatitis and ulcerative colitis. The funding will also support development of TRB-071 and their discovery engine.
By: Lei Lei Wu
Bluebird reports 17 people with sickle cell disease started receiving Lyfgenia gene therapy, with 35 starting Zynteglo for thalassemia and 5 starting Skysona for cerebral adrenoleukodystrophy. The company reported $10.6 million in Q3 revenue and expects $25 million next quarter, amid financial challenges.
Tune Therapeutics announced Thursday that New Zealand health authorities are allowing the company to study its experimental epigenetic editing therapy for …
(833) 317-6278 
